The molecular genetics and morphometry-based Endometrial Intraepithelial Neoplasia classification system predicts disease progression in Endometrial hyperplasia more accurately than the 1994 World Health Organization classification system

被引:120
作者
Baak, JP
Mutter, GL
Robboy, S
van Diest, PJ
Uyterlinde, AM
Orbo, A
Palazzo, J
Fiane, B
Lovslett, K
Burger, C
Voorhorst, F
Verheijen, RH
机构
[1] Univ Bergen, Gade Inst, Dept Pathol, Bergen, Norway
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[4] Univ Med Ctr, Dept Pathol, Utrecht, Netherlands
[5] Canisus Wilhelmina Ziekenhuis Hosp, Dept Pathol, Nijmegen, Netherlands
[6] Univ Tromso, Inst Med Biol, Dept Pathol, Tromso, Norway
[7] Jefferson Med Coll, Dept Pathol, Philadelphia, PA USA
[8] Stavanger Univ Hosp, Dept Gynaecol, Stavanger, Norway
[9] Erasmus Sch Ctr, Dept Gynecol, Rotterdam, Netherlands
[10] Vrije Univ Amsterdam, Med Ctr, Dept Gynecol, Amsterdam, Netherlands
[11] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands
关键词
endometrial hyperplasia; progression; World Health Organization; endometrial intraepithelial neoplasia;
D O I
10.1002/cncr.21058
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The objective of this study was to compare the accuracy of disease progression prediction of the molecular genetics and morphometry-based Endometrial Intraepithelial Neoplasia (EIN) and World Health Organization 1994 (WHO94) classification systems in patients with endometrial hyperplasias. METHODS. A multicenter, multivariate analysis was conducted on 477 patients with endometrial hyperplasia who were required to have a 1-year minimum disease-free interval from the time of the index biopsy (1-18 years of follow-up). The results from that analysis were compared with the results from 197 patients who had < 1 year of follow-up. RESULTS. Twenty-four of 477 hyperplasias (5.0%) progressed to malignant disease over an average of 4 years (maximum, 10 years). According to the WHO94 classification, 16 of 123 atypical hyperplasias (13%) and 8 of 354 nonatypical hyperplasias (2.3%) progressed (hazard ratio [HR] = 7). Twenty-two of 118 EINs (19%) and 2 of 359 non-EINs (0.6%) progressed (HR = 45). FIN was prognostic within each WHO94 subcategory. Progression rates were 3% in simple hyperplasias, 22% in complex hyperplasias, 17% in simple atypical hyperplasias, and 38% in complex atypical hyperplasias with EIN, compared with progression rates of 0.0-2.0% in all hyperplasias if EIN was absent. EIN detected precancerous lesions (sensitivity, 92%) better than WHO94 atypical hyperplasias collectively (67%) or complex atypical hyperplasias alone (46%). In a Cox regression analysis, EIN was the strongest prognostic index of future endometrial carcinoma. The same was true for patients with < 1 year of follow-up (HR for EIN, atypical hyperplasia, and complex atypical hyperplasia: 58, 7, and 8, respectively). CONCLUSIONS. The EIN classification system predicted disease progression more accurately than the WHO94 classification and identified many women with benign changes that would have been regarded as high risk according to the WHO94 classification system.
引用
收藏
页码:2304 / 2312
页数:9
相关论文
共 29 条
[1]   ENDOMETRIAL INTRAEPITHELIAL CARCINOMA - A DISTINCTIVE LESION SPECIFICALLY ASSOCIATED WITH TUMORS DISPLAYING SEROUS DIFFERENTIATION [J].
AMBROS, RA ;
SHERMAN, ME ;
ZAHN, CM ;
BITTERMAN, P ;
KURMAN, RJ .
HUMAN PATHOLOGY, 1995, 26 (11) :1260-1267
[2]  
ANDERSON MC, 2002, PATHOLOGY FEMALE REP, P305
[3]  
Baak JP, 1991, Manual of quantitative pathology in cancer diagnosis and prognosis
[4]   ARCHITECTURAL AND NUCLEAR MORPHOMETRICAL FEATURES TOGETHER ARE MORE IMPORTANT PROGNOSTICATORS IN ENDOMETRIAL HYPERPLASIAS THAN NUCLEAR MORPHOMETRICAL FEATURES ALONE [J].
BAAK, JPA ;
NAUTA, JJP ;
WISSEBREKELMANS, ECM ;
BEZEMER, PD .
JOURNAL OF PATHOLOGY, 1988, 154 (04) :335-341
[5]   Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in International Federation of Gynecology and Obstetrics stage 1 and 2 endometrial carcinoma [J].
Baak, JPA ;
Snijders, W ;
van Diermen, B ;
van Diest, PJ ;
Diepenhorst, FW ;
Benraadt, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4214-4221
[6]   Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias [J].
Baak, JPA ;
Orbo, A ;
van Diest, PJ ;
Jiwa, M ;
de Bruin, P ;
Broeckaert, M ;
Snijders, W ;
Boodt, PJ ;
Fons, G ;
Burger, C ;
Verheijen, RHM ;
Houben, PWH ;
The, HS ;
Kenemans, P .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (07) :930-935
[7]   DISCRIMINATION OF HYPERPLASIA AND CARCINOMA OF THE ENDOMETRIUM BY QUANTITATIVE MICROSCOPY - A FEASIBILITY STUDY [J].
BAAK, JPA ;
KURVER, PHJ ;
DIEGENBACH, PC ;
DELEMARRE, JFM ;
BREKELMANS, ECM ;
NIEUWLAAT, JE .
HISTOPATHOLOGY, 1981, 5 (01) :61-68
[8]   THE ADDITIONAL PROGNOSTIC VALUE OF MORPHOMETRIC NUCLEAR ARRANGEMENT AND DNA-PLOIDY TO OTHER MORPHOMETRIC AND STEREOLOGIC FEATURES IN ENDOMETRIAL HYPERPLASIAS [J].
BAAK, JPA ;
KUIK, DJ ;
BEZEMER, PD .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1994, 4 (05) :289-297
[9]   Does hysteroscopy improve upon the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? [J].
Ben-Yehuda, OM ;
Kim, YB ;
Leuchter, RS .
GYNECOLOGIC ONCOLOGY, 1998, 68 (01) :4-7
[10]   A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens [J].
Bergeron, C ;
Nogales, FF ;
Masseroli, M ;
Abeler, V ;
Duvillard, P ;
Müller-Holzner, E ;
Pickartz, H ;
Wells, M .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (09) :1102-1108